Hedge Fund - Deerfield Management

In a couple of filings with the Securities and Exchange Commission, Deerfield Management, led by James E.

James E. Flynn's healthcare-focused Deerfield Management has revealed, in a new filing with the SEC, initiating a passive stake in Horizon Pharma Inc (NASDAQ:HZNP).

Deerfield Management, managed by James E. Flynn, has boosted its exposure in Universal American Corporation (NYSE:UAM) to 4.4 million shares, from around 2.9 million reported in the latest 13F.

A new filing with the Securities and Exchange Commission has revealed that James E. Flynn, and his hedge fund Deerfield Management now hold a 4.01% stake in Cancer Genetics Inc (NASDAQ:CGIX).

In a new 13G filing, James E. Flynn and his fund Deerfield Management reported a position in MEI Pharma Inc (NASDAQ:MEIP), which represents 6.38% of the company.

James Flynn, Deerfield: Prosensa Holding NV (NASDAQ:RNA) recently became an addition in the equity portfolio of Deerfield Management, managed by James E. Flynn.

In the eyes of many investors, hedge funds are perceived as overrated, old financial vehicles of a forgotten age.

In the eyes of many of your peers, hedge funds are seen as useless, old investment tools of a forgotten age.